MX2019014199A - Tratamiento de combinacion antineoplasico. - Google Patents

Tratamiento de combinacion antineoplasico.

Info

Publication number
MX2019014199A
MX2019014199A MX2019014199A MX2019014199A MX2019014199A MX 2019014199 A MX2019014199 A MX 2019014199A MX 2019014199 A MX2019014199 A MX 2019014199A MX 2019014199 A MX2019014199 A MX 2019014199A MX 2019014199 A MX2019014199 A MX 2019014199A
Authority
MX
Mexico
Prior art keywords
combination therapy
cancer combination
cancer
antagonists
binding molecules
Prior art date
Application number
MX2019014199A
Other languages
English (en)
Spanish (es)
Inventor
Solca Flavio
Hilberg Frank
Reschke Markus
Hans Hofmann Marco
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019014199A publication Critical patent/MX2019014199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2019014199A 2017-06-02 2018-06-01 Tratamiento de combinacion antineoplasico. MX2019014199A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17174323 2017-06-02
EP17196949 2017-10-17
PCT/EP2018/064445 WO2018220169A1 (en) 2017-06-02 2018-06-01 Anti-cancer combination therapy

Publications (1)

Publication Number Publication Date
MX2019014199A true MX2019014199A (es) 2020-01-23

Family

ID=62386492

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014199A MX2019014199A (es) 2017-06-02 2018-06-01 Tratamiento de combinacion antineoplasico.

Country Status (13)

Country Link
US (2) US11198726B2 (enExample)
EP (1) EP3630822A1 (enExample)
JP (1) JP2020521797A (enExample)
KR (1) KR20200013231A (enExample)
CN (1) CN110691790A (enExample)
AU (1) AU2018277227A1 (enExample)
BR (1) BR112019022074A2 (enExample)
CA (1) CA3061053A1 (enExample)
CL (1) CL2019003430A1 (enExample)
IL (1) IL270905A (enExample)
MX (1) MX2019014199A (enExample)
PH (1) PH12019502692A1 (enExample)
WO (1) WO2018220169A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016075037A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
CA2963719A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-il-1beta antibodies and methods of use
WO2016075035A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
CN110691790A (zh) * 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
IL302034A (en) 2020-11-04 2023-06-01 Heidelberg Pharma Res Gmbh Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy
CA3208117A1 (en) 2021-03-19 2022-09-22 Torsten HECHLER B-lymphocyte specific amatoxin antibody conjugates
JP2024534964A (ja) * 2021-09-10 2024-09-26 ソーター・バイオファーマ・プライベイト・リミテッド 抗ａｎｇ２抗体、その調製方法及び使用
IL320168A (en) 2022-11-01 2025-06-01 Heidelberg Pharma Res Gmbh Anti-gucy2c antibody and uses thereof
KR20250152101A (ko) 2023-03-13 2025-10-22 하이델베르크 파마 리서치 게엠베하 암 치료에의 사용을 위한 피하 투여 항체-약물 접합체
WO2025189977A1 (zh) * 2024-03-13 2025-09-18 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
RU2007117752A (ru) 2004-10-13 2008-11-20 Аблинкс Н.В. (Be) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
JP4361545B2 (ja) 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
EP2479191A3 (en) 2005-05-18 2013-03-13 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
CA2715166C (en) 2008-02-11 2017-05-16 Curetech Ltd. Monoclonal antibodies for tumor treatment
CN101965362A (zh) 2008-03-05 2011-02-02 埃博灵克斯股份有限公司 新型抗原结合二聚体-复合物及其制备方法和应用
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
IN2014DN06904A (enExample) * 2012-03-30 2015-05-15 Boehringer Ingelheim Int
KR20150060687A (ko) * 2012-09-28 2015-06-03 베링거 인겔하임 인터내셔날 게엠베하 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF-R 제제를 포함하는 약제학적 조합물
WO2014049100A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2016170039A1 (en) * 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide
CN107406502A (zh) 2015-04-23 2017-11-28 豪夫迈·罗氏有限公司 结合血管生成素2的抗体与结合编程性死亡配体1的抗体的组合疗法
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
HUE053452T2 (hu) * 2016-05-18 2021-07-28 Boehringer Ingelheim Int Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
CN110691790A (zh) * 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
US10793634B2 (en) * 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies

Also Published As

Publication number Publication date
KR20200013231A (ko) 2020-02-06
US11198726B2 (en) 2021-12-14
IL270905A (en) 2020-01-30
US20220340651A1 (en) 2022-10-27
CL2019003430A1 (es) 2020-05-08
CN110691790A (zh) 2020-01-14
EP3630822A1 (en) 2020-04-08
BR112019022074A2 (pt) 2020-05-12
CA3061053A1 (en) 2018-12-06
PH12019502692A1 (en) 2020-07-13
WO2018220169A1 (en) 2018-12-06
JP2020521797A (ja) 2020-07-27
AU2018277227A1 (en) 2019-10-31
US20180346559A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
PH12019502692A1 (en) Anti-cancer combination therapy
CL2019002850A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3.
MX2025009223A (es) Agentes de union a clec9a y su uso
MX2023010042A (es) Polinucleotidos moduladores.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
SA517381167B1 (ar) عامل علاجي مستحث للسمية الخلوية
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201992757A1 (ru) Биспецифические антитела-ингибиторы контрольной точки
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
EP4413985A3 (en) Pharmaceutical compounds
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MA39906A (fr) Polythérapies pour le traitement du cancer
MX2020006116A (es) Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
HK1249469A1 (zh) 用RORγ抑制剂治疗癌症的方法
PH12019502002A1 (en) Combination theraphy
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2020004476A (es) Compuestos piridinicos de pladienolida y metodos de uso.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2016014559A (es) Compuestos para el tratamiento de cancer.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
EA201990370A1 (ru) Терапия рака, связанная с crebbp
MX2018011219A (es) Trail diseñado por ingenieria para terapia de cancer.